thalidomide has been researched along with Ambulation Disorders, Neurologic in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects." | 1.33 | Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suyanı, E | 1 |
| Yağcı, M | 1 |
| Sucak, GT | 1 |
| Giannini, F | 1 |
| Volpi, N | 1 |
| Rossi, S | 1 |
| Passero, S | 1 |
| Fimiani, M | 1 |
| Cerase, A | 1 |
| Fleming, FJ | 1 |
| Vytopil, M | 1 |
| Chaitow, J | 1 |
| Jones, HR | 1 |
| Darras, BT | 1 |
| Ryan, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
3 other studies available for thalidomide and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Gait Disorders, N | 2011 |
Thalidomide-induced neuropathy: a ganglionopathy?
Topics: Aged; Evoked Potentials, Somatosensory; Gait Disorders, Neurologic; Ganglia, Spinal; Humans; Magneti | 2003 |
Thalidomide neuropathy in childhood.
Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy | 2005 |